Genentech Inc. is pushing a “value-based” approach to pricing combination therapy that would allow for reduced list prices for its Tecentriq (atezolizumab) and Avastin (bevacizumab) when used in combination for lung cancer patients.
The company has been in discussions with HHS, FDA and the Centers for Medicare and Medicaid Services to advance the policy, which it calls the Combination Pricing Pilot, a company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?